Apellis (APLS) Gains in Active Trading for June 23

Equities Staff  |

Apellis Pharmaceuticals Inc (NASDAQ:APLS) stock was among today's market movers, finishing trading higher 6.87% to $47.00 on June 23.

1,024,856 shares exchanged hands while the 30-day daily average of 855,709 shares.

The company's stock has risen 6.98% so far in 2022.

Apellis shares have moved between $27.50 and $73.00 over the past twelve months.

The company is set to release earnings on 2022-08-08.

For technical charts, analysis, and more on Apellis visit the company profile.

About Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that is committed to leveraging courageous science, creativity, and compassion to deliver life-changing therapies. Leaders in targeted C3 therapies, the company aims to develop transformative therapies for a broad range of debilitating diseases that are driven by excessive activation of the complement cascade, including those within hematology, ophthalmology, nephrology, and neurology.

To get more information on Apellis Pharmaceuticals Inc and to follow the company's latest updates, you can visit the company's profile page here: Apellis Pharmaceuticals Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Trending Articles

Will Mining Stocks Fall Further?
3 Reasons To Be Optimistic About the Global Shipping Industry
The Best Laid Plans of Mice and Men — Part II
Why I’m Buying the 'New' Value Stocks

Market Movers

Sponsored Financial Content